Thienopyridine Resistance Among Patients Undergoing Intracoronary Stent Implantation and Treated With Dual Antiplatelet Therapy: Assessment of Some Modifying Factors

Journal of Pharmacological Sciences

Danilo Vojvodic³  Zoran Todorovic²  Nina Djukanovic¹  Aleksandra Grdinic⁴  Miodrag Ostojic¹  Milica Prostran² 

[1] Department of Cardiology, Institute for Cardiovascular Diseases, Clinical Centre of Serbia, Serbia;Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade, Serbia;Institute for Medical Research, Military Medical Academy, Serbia;Department of Cardiology, Clinical Center Dr. Dragisa Misovic, Serbia

关键词: antiplatelet agent;    stent;    vasodilator-stimulated phosphoprotein (VASP) assay;   

DOI  :  10.1254/jphs.08077SC

学科分类：药学

来源: Nihon Yakuri Gakkai Henshuubu / Japanese Pharmacological Society

【 摘 要 】

References(15)Cited-By(5)In this open, prospective study we assessed the prevalence of antiplatelet resistance among patients subjected to intracoronary stent implantation. In patients treated with aspirin + thienopyridine (N = 32), platelet reactivity index (PRI) significantly decreased after 2 and 7 days of dual antiplatelet treatment in comparison with the same patients on aspirin monotherapy (P<0.001, both). After 7 days of aspirin + thienopyridine treatment, insufficient antiplatelet response was observed in 28% (9/32) of the patients. High interindividual variability in response to aspirin + thienopyridine treatment emphasizes the significance of thienopyridine resistance, while the influence of statins on such a treatment should be reassessed.

【 授权许可】

Unknown